Latest News in the pharma Industry
Research & Development
New formulation of Oncaspar receives Marketing Authorization in Europe for patients with ALL
14 Dec 2017
Freeze-dried, or lyophilized, formulation aims to improve supply management by providing the same dosing regimen as liquid Oncaspar but with a three-times longer shelf life of up to 24 months.
Read more
CMC Biologics and Harpoon Therapeutics collaborate on exciting new TriTAC molecules
14 Dec 2017
First clinical candidate, HPN424, is in development for the treatment of metastatic prostate cancer and expected to enter Phase I clinical trials in 2018.
Read more
Sanofi ends development of Clostridium difficile vaccine
4 Dec 2017
IDMC concludes that the study is unlikely to meet its primary objective.
Read more.png)
Novartis' Ultibro Breezhaler significantly improved COPD patients' lung function after direct switch from Seretide
29 Nov 2017
Study provides further evidence that it is possible to reduce the burden of long-term inhaled steroids in many COPD patients.
Read more.jpg)
Company's new identity integrates services typically found in disparate CDMOs and CROs
20 Nov 2017
Quotient Sciences Translational Pharmaceutics platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research.
Read more
New treatments to solve global antibiotic crisis could reach the market by 2020
19 Nov 2017
New ARB technology rejuvenates existing antibiotics to outsmart antibiotic resistance.
Read more.png)
Bavencio becomes first treatment for rare skin cancer mMCC licensed for use in the UK
7 Nov 2017
The launch of avelumab marks a step-change in the way that mMCC can be treated.
Read more.png)
Novartis seeks leadership with Cosentyx
6 Nov 2017
For the first time for any biologic, data show almost 80% of ankylosing spondylitis patients on Cosentyx have no radiographic progression of the spine at 4 years.
Read more.jpg)
NousCom raises €42 million to develop off-the-shelf cancer vaccine
6 Nov 2017
Financing to advance its pipeline of neoantigen cancer-based immunotherapies to the clinic.
Read more.png)
RA patients treated with baricitinib reported greater improvements in pain compared with adalimumab
5 Nov 2017
Post-hoc analysis shows pain improvement was consistent regardless of a patient's baseline pain severity.
Read more
RedHill Biopharma and IntelGenx submit NDA to FDA for Rizaport for migraines
2 Nov 2017
Rizaport is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines.
Read more
Cristal Therapeutics progresses nanomedicine CriPec-docetaxel to Phase Ib development
1 Nov 2017
This nanomedicine candidate is specifically designed to enable enhanced tumour accumulation and local drug release at the target site, to boost the therapeutic efficacy and to overcome the shortfalls associated with current docetaxel products.
Read more